Corporate Social Responsibility in Non- Controlled Joint Venture Assets: Why Corporate Boards Should Care
Bookmark

Corporate Social Responsibility in Non- Controlled Joint Venture Assets: Why Corporate Boards Should Care

$0.00

Water Street Partners

Category: Tags: , , , ,

Additional information

Language

Capability

Description

LAST YEAR, we wrote about why corporate Boards of Directors should care about their portfolios of non-controlled joint ventures. In short, these portfolios tend to be more material than realized, carry underappreciated and often inappropriately managed levels of risk, and contain latent performance upside – all of which are challenges to corporate Directors increasingly exposed collectively and personally to regulatory and shareholder scrutiny.

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.

You may also like

  • LEK

    As the construction industry starts its long climb up from the greatest collapse in recent history, companies are looking to repair the damage done by anxious suppliers who ceded margins to (unsuccessfully) maintain volumes. While this dynamic is perhaps most acute in the building materials markets, it is certainly not unique and can be seen across a wide range of commodity and manufacturing sectors.

    Rethinking Pricing Strategies in Commoditized Markets: Network-based Best Alternative Pricing

    $0.00     LEK
  • ORBIT2transformation

    To get a sense of the potential of digitization in procurement, picture this: It’s 2020. Hybrid cloud solutions, RPA and blockchain are in place. P2P is highly streamlined with zero-touch options. As a next-gen Chief Procurement Officer, your day starts with browsing through a virtual supplier screen that displays a status report on expiring contracts, feedback from suppliers on contractual negotiations, RFX launched on open markets and so on.

    Procurement 4.0 Preparing for Digital Transformation

    $0.00     ORBIT2transformation
  • McKinsey

    In 2007, medical leaders from across the pharmaceutical industry assembled to develop a common understanding of a ten-year vision for Medical Affairs. With five years now past, it is hardly surprising that significant change has occurred in the world in which the pharmaceutical industry operates, especially given the remarkable economic environment and the continued acceleration of technological change.

    Pharma Medical Affairs 2020 and beyond

    $0.00     McKinsey

Pin It on Pinterest

Loading..